Skip to main navigation
Telesis Bio Logo
    • Home
    • Products
      • Coronavirus
        • RNA controls
        • Synthetic genomes
        • Services
        • Resources
      • BioXp™ system
        • Gene synthesis
        • DNA cloning
        • Libraries
        • Resources
      • Benchtop reagents
        • Gibson assembly kits
        • RapidAMP kits
        • Vmax X2 cells
        • Resources
      • Services
        • Contact
    • Workflows
      • Research applications
        • Antibody drug discovery
        • Genome editing
        • Metabolic engineering
      • Clinical applications
        • Precision medicine
        • Vaccine development
        • Immune monitoring
        • Regenerative medicine
    • Innovation
      • SOLA Technology
    • About
      • Leadership
      • Careers
      • Press + news
      • Distributors
      • Events
      • Legal
      • Blog
    • Investors
      • News & Events
      • Stock Info
      • Corporate Governance
      • Financials & Filings
      • IR Resources
    • Order
    • Contact
  • Order
  • Support

Investor Relations

  • Investors
  • News + events
    • News Releases
    • Events
    • Presentations
  • Stock information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Analyst Coverage
  • Corporate governance
    • Governance Overview
    • Board of Directors
    • Management
    • Committee Composition
  • Financials + filings
    • SEC Filings
    • Annual Reports & Proxies
    • Quarterly Results
  • IR resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

Quarterly Results

Financials and Filings Menu

Financials and Filings Menu

  • SEC Filings
  • |
  • Annual report + proxy
  • |
  • Quarterly Results
Show all

2022

Q3

  • Telesis Bio Inc. Reports Third Quarter 2022 Financial Results
  • Q3 2022 Codex DNA Inc, Earnings Conference Call
  • Form 10-Q

Q2

  • Codex DNA Reports Second Quarter 2022 Financial Results
  • Q2 2022 Codex DNA Inc, Earnings Conference Call
  • Form 10-Q

Q1

  • Codex DNA Reports First Quarter 2022 Financial Results
  • Q1 2022 Codex DNA Inc, Earnings Conference Call
  • Form 10-Q

2021

Q4

  • Codex DNA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Guidance
  • Q4 2021 Codex DNA Inc, Earnings Conference Call
  • Form 10-K

Q3

  • Codex DNA Reports Third Quarter 2021 Financial Results
  • Q3 2021 Codex DNA Inc, Earnings Conference Call
  • Form 10-Q

Q2

  • Codex DNA Reports Second Quarter 2021 Financial Results
  • Q2 2021 Codex DNA Inc, Earnings Conference Call
  • Form 10-Q

About Telesis Bio

Telesis Bio Inc. is building biology. Creators of the BioXp® system, the world’s only fully automated gene synthesis platform, and the industry-standard Gibson Assembly® method, Telesis Bio Inc. is focused on enabling researchers with the tools they need to rapidly and securely design, code, and create synthetic DNA.

Telesis Bio Inc. is accelerating advances in the fields of personalized medicine, biologics drug discovery, vaccine development, genome editing, and cell and gene therapy.

Site

  • Products
  • Workflows
  • Support
  • About
  • Investors
  • Order
  • Contact

Links

  • Events
  • Blog
  • Careers
  • Terms of use
  • Cookie policy
  • Privacy policy
  • Legal

© 2023 Telesis Bio Inc. All rights reserved.

Telesis Bio Logo